Coherus Bio (CHRS)

$0.78 +0.02 (2.09%)
Market Cap 90.31M
Revenue (ttm) 266.96M
Net Income (ttm) 28.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.68%
Debt to Equity Ratio -0.20
Volume 1,822,400
Avg Vol 1,708,078
Day's Range N/A - N/A
Shares Out 115.93M
Stochastic %K 30%
Beta 1.01
Analysts Strong Sell
Price Target $5.26

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 649 3530
Address:
333 Twin Dolphin Drive, Suite 600, Redwood City, United States
normansteve
normansteve Oct. 4 at 4:44 PM
$CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Oct 3, 2025 https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-announces-poster-presentation-40th-annual
0 · Reply
Me0wth
Me0wth Oct. 3 at 8:28 PM
$AKBA $BCRX $CERS $CHRS $ESPR 1 year bio tech challenge. 5 bio techs, 1000 dollars in each. No adding, no selling for 1 year. Started on November 29, 2024 I’ll take it, a few more weeks until the final results 🤓
2 · Reply
Mizee
Mizee Oct. 3 at 4:01 PM
$CHRS Green day
0 · Reply
simonig1
simonig1 Oct. 3 at 3:08 PM
$CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Link: https://www.fidelity.com/news/article/default/202510030905PRIMZONEFULLFEED9539692?print=true
0 · Reply
GoWhiteSox
GoWhiteSox Oct. 3 at 2:55 PM
$CHRS https://www.stocktitan.net/news/CHRS/coherus-oncology-announces-poster-presentation-at-the-40th-annual-19xmdjdcw3hj.html
0 · Reply
BigDaddyCapital
BigDaddyCapital Oct. 3 at 2:48 PM
$CHRS shorts holding this down hard 1.69-1.71. Some big whale needs to come in and break through those points
0 · Reply
TeamDSM
TeamDSM Oct. 3 at 2:38 PM
$CHRS I wanted to sell at 1.70 not all. I feel it’s hard to hold when you’re told to sell the shares that are in profit.
0 · Reply
Mirbo63
Mirbo63 Oct. 3 at 2:00 PM
$CHRS Row,Row,Row,Row
0 · Reply
LORAXX
LORAXX Oct. 3 at 1:54 PM
$CHRS Coherus Oncology To Present CHS-114 Anti-CCR8 Data At SITC 2025 And Highlight Mechanism In Cancer IO Webinar Series BENZINGA 9:10 AM ET 10/3/2025
0 · Reply
wall_e_street
wall_e_street Oct. 3 at 1:40 PM
$CHRS Seeing what the price has done in the last few days, I think there won’t be a cup and handle, and we’re going to continue with the bullish trend and break 1.70, maybe even today.
0 · Reply
Latest News on CHRS
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 3, 2025, 9:05 AM EDT - 1 day ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 5:02 PM EDT - 3 days ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Coherus Oncology: Five Readouts Or More Possible In 2026

Oct 1, 2025, 10:43 AM EDT - 3 days ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Coherus Oncology: On The Shaping Up

Aug 25, 2025, 4:55 PM EDT - 5 weeks ago

Coherus Oncology: On The Shaping Up

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 11:35 AM EDT - 2 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:41 PM EDT - 2 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 31, 2025, 4:45 PM EDT - 2 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:46 PM EDT - 5 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:15 PM EDT - 5 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 5, 2025, 4:01 PM EDT - 5 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus to Participate in Upcoming Investor Conferences

May 1, 2025, 5:04 PM EDT - 5 months ago

Coherus to Participate in Upcoming Investor Conferences

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 28, 2025, 10:10 AM EDT - 5 months ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 17, 2025, 5:53 AM EDT - 6 months ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Apr 14, 2025, 8:00 AM EDT - 6 months ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 6 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 8:52 PM EDT - 7 months ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:12 PM EDT - 7 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Mar 3, 2025, 8:30 AM EST - 7 months ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 9:08 AM EST - 7 months ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 18, 2024, 8:30 AM EST - 10 months ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16, 2024, 6:08 PM EST - 10 months ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Dec 3, 2024, 9:34 AM EST - 10 months ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 27, 2024, 4:01 PM EST - 11 months ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:09 PM EST - 11 months ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:01 PM EST - 11 months ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31, 2024, 12:04 PM EDT - 1 year ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:51 PM EDT - 1 year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 23, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

May 10, 2024, 12:07 AM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 9, 2024, 7:30 AM EDT - 1 year ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024, 4:30 PM EDT - 1 year ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:02 AM EDT - 1 year ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 20, 2024, 8:14 PM EDT - 1 year ago

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 8:56 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 5, 2024, 4:01 PM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Coherus Completes Divestiture of Ophthalmology Franchise

Mar 4, 2024, 1:00 AM EST - 1 year ago

Coherus Completes Divestiture of Ophthalmology Franchise

Coherus BioSciences Announces New Employment Inducement Grants

Feb 23, 2024, 5:33 PM EST - 1 year ago

Coherus BioSciences Announces New Employment Inducement Grants

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 21, 2024, 8:30 AM EST - 1 year ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Feb 5, 2024, 8:00 AM EST - 1 year ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 22, 2024, 1:15 AM EST - 1 year ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

normansteve
normansteve Oct. 4 at 4:44 PM
$CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Oct 3, 2025 https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-announces-poster-presentation-40th-annual
0 · Reply
Me0wth
Me0wth Oct. 3 at 8:28 PM
$AKBA $BCRX $CERS $CHRS $ESPR 1 year bio tech challenge. 5 bio techs, 1000 dollars in each. No adding, no selling for 1 year. Started on November 29, 2024 I’ll take it, a few more weeks until the final results 🤓
2 · Reply
Mizee
Mizee Oct. 3 at 4:01 PM
$CHRS Green day
0 · Reply
simonig1
simonig1 Oct. 3 at 3:08 PM
$CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Link: https://www.fidelity.com/news/article/default/202510030905PRIMZONEFULLFEED9539692?print=true
0 · Reply
GoWhiteSox
GoWhiteSox Oct. 3 at 2:55 PM
$CHRS https://www.stocktitan.net/news/CHRS/coherus-oncology-announces-poster-presentation-at-the-40th-annual-19xmdjdcw3hj.html
0 · Reply
BigDaddyCapital
BigDaddyCapital Oct. 3 at 2:48 PM
$CHRS shorts holding this down hard 1.69-1.71. Some big whale needs to come in and break through those points
0 · Reply
TeamDSM
TeamDSM Oct. 3 at 2:38 PM
$CHRS I wanted to sell at 1.70 not all. I feel it’s hard to hold when you’re told to sell the shares that are in profit.
0 · Reply
Mirbo63
Mirbo63 Oct. 3 at 2:00 PM
$CHRS Row,Row,Row,Row
0 · Reply
LORAXX
LORAXX Oct. 3 at 1:54 PM
$CHRS Coherus Oncology To Present CHS-114 Anti-CCR8 Data At SITC 2025 And Highlight Mechanism In Cancer IO Webinar Series BENZINGA 9:10 AM ET 10/3/2025
0 · Reply
wall_e_street
wall_e_street Oct. 3 at 1:40 PM
$CHRS Seeing what the price has done in the last few days, I think there won’t be a cup and handle, and we’re going to continue with the bullish trend and break 1.70, maybe even today.
0 · Reply
SybilDorsett
SybilDorsett Oct. 3 at 1:08 PM
$CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – GLOBENEWSWIRE 9:05 AM ET 10/3/2025
0 · Reply
cjwashington
cjwashington Oct. 3 at 12:44 PM
$CHRS up up up
0 · Reply
winners234
winners234 Oct. 3 at 8:35 AM
$RSVN $CHRS $GIPR $BURU
1 · Reply
HansDampf1
HansDampf1 Oct. 3 at 8:11 AM
$CHRS coherus in focus https://www.sharedeals.de/coherus-oncology-nach-der-rallye-folgt-der-durchbruch/coherus-oncology-nach-der-rallye-folgt-der-durchbruch?utm_source=FN&utm_medium=rss&utm_campaign=coherus-oncology-nach-der-rallye-folgt-der-durchbruch
0 · Reply
TeamDSM
TeamDSM Oct. 3 at 3:46 AM
$CHRS Has anyone used an AI auto trading program?
0 · Reply
Microcap777
Microcap777 Oct. 2 at 8:29 PM
$CHRS It's been a humdrum few days, but hey ... we started this week at 1.50 and have held onto a good portion of Monday's gains. If we go up a dime a week and continue setting new highs and lower lows, then I am totally fine with that.
0 · Reply
cjwashington
cjwashington Oct. 2 at 8:03 PM
$CHRS lets see 1.70 ++++ after hours, would be amazing!!!!
0 · Reply
Microcap777
Microcap777 Oct. 2 at 7:41 PM
$CHRS Unfortunately, this is offset by about 43K in CHRS losses in other accounts but I will take the green. With that said, I am not selling anytime soon and neither should you.
2 · Reply
normansteve
normansteve Oct. 2 at 7:23 PM
$CHRS Sell ​​order set.... at $8. If they want the shares, they should pay for them.
1 · Reply
Cowpokecaleb
Cowpokecaleb Oct. 2 at 7:06 PM
$CHRS
0 · Reply
Mizee
Mizee Oct. 2 at 7:05 PM
$CHRS power hour
0 · Reply
normansteve
normansteve Oct. 2 at 5:21 PM
$CHRS And the accumulation continues. Will it take off soon? Watch for a probable break above $1.70.
0 · Reply